What records are connected here?
- Evidence lanes
- 2
- Source years
- 9
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,5Evidence: Large human trialsInflammation and immune · Infections
Also called Timunox1
Thymopentin is a synthetic five-amino-acid peptide (Arg-Lys-Asp-Val-Tyr) matching positions 32 to 36 of thymopoietin, and studied as a modulator of the immune system.1 Randomized trials from the 1990s had mixed results: it did not clear chronic hepatitis B or significantly cut infections after surgery, and in a 352-person HIV trial it reduced progression only in people who had already taken AZT for longer.2,3,4 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,5,7
| What it is | A synthetic pentapeptide matching residues 32 to 36 of thymopoietin, also recorded as TP-5 and under the brand names Timunox and Sintomodulina, according to FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,5 |
| Human evidence | Randomized trials from the 1990s in HIV infection, chronic hepatitis B and cancer surgery, with mixed results.2,3,4 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Thymopentin is a synthetic peptide of five amino acids, arginine, lysine, aspartic acid, valine and tyrosine, matching positions 32 to 36 of thymopoietin.1
FDA’s substance registry also records it as TP-5, thymopoietin pentapeptide and the brand names Timunox, Sintomodulina and Immunox.1
It was studied as a modulator of the immune system. In the 1994 surgery trial, it prevented the fall in CD3- and CD4-positive T cells after operations in older patients.4
In the 1995 HIV trial it did not change CD4 counts or p24 antigen levels compared with placebo.2
A 48-week randomized, double-blind trial in 352 people with HIV taking AZT found fewer cases of AIDS or death with thymopentin among those who had taken AZT for more than six months (2 versus 10), but no significant difference among those who had taken it for less (4 versus 0). Adverse reactions were not more common than with placebo.2
In a randomized trial of 206 people having major surgery for stomach or colorectal cancer, the infection rate was 17.5% with thymopentin and 24.3% without it, a difference that was not significant.4
In a randomized trial of 30 people with chronic hepatitis B, the authors concluded that six months of thymopentin was not effective.3
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of thymopentin by FDA.1,5
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list thymopentin.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymopentin is not among them.6,7
Whether the benefit seen in one group of the HIV trial would hold up: in the other group there was no benefit, and HIV treatment has changed since the 1990s.2
Whether it helps any condition reliably: the trials reviewed here had mixed or negative results.3,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Thymopentin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Thymopentin are a bounded selection, not every registration or paper about Thymopentin. For the years before Thymopentin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Thymopentin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Thymopentin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied in clinical trials. A 352-person HIV trial found benefit in one subgroup only; smaller trials in hepatitis B and cancer surgery found no significant benefit. Thymopentin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied in clinical trials. A 352-person HIV trial found benefit in one subgroup only; smaller trials in hepatitis B and cancer surgery found no significant benefit. Thymopentin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 20, 2026
Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.↗Source date October 20, 2026Literature metadata · added November 16, 2026
Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.↗Source date October 20, 2026Literature metadata · added November 16, 2026
Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy.↗Source date October 11, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00002049 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.
PeptideScanner retained ClinicalTrials.gov record NCT00002050 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.
PeptideScanner retained ClinicalTrials.gov record NCT00002051 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span June 24, 2005 to October 20, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 2863860 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 3898297 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 3898294 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9638477 in Immunologic research as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 1998 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39814680 in Chembiochem : a European journal of chemical biology as Journal Article, with publication-date metadata of 2025-02-04 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39002910 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2024-07-11 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35234086 in Drug development and industrial pharmacy as Journal Article, with publication-date metadata of 2022-03-15 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32263105 in Journal of materials chemistry. B as Journal Article, with publication-date metadata of 2015-12-24 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2994196 in Survey of immunologic research as Journal Article, Review, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 3898285 in Survey of immunologic research as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2657246 in Medical oncology and tumor pharmacotherapy as Journal Article, Review, with publication-date metadata of 1989 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2663371 in Current problems in dermatology as Journal Article, Review, with publication-date metadata of 1989 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · Official source · Source checked November 16, 2026
Journal of Hepatology · Official source · Source checked November 16, 2026
The British Journal of Surgery · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026